| 摘要 |
PCT No. PCT/SE86/00144 Sec. 371 Date Nov. 20, 1986 Sec. 102(e) Date Nov. 20, 1986 PCT Filed Mar. 27, 1986 PCT Pub. No. WO86/05814 PCT Pub. Date Oct. 9, 1986.The invention relates to a fully solubilizable fibrin based composition, which is characterized by the combination that the fibrin is desAA-fibrin or desAA-fibrin from which the C-terminal portions of the alpha -chains have been removed by enzymatic digestion, and that the solubilizing agent is a tetrapeptide containing the amino acid sequence -L-prolyl-L-arginyl-, preferably glycyl-L-prolyl-L-arginyl-L-prolin. The full solubility of the fibrin makes possible new uses within the area of determination of important fibrinolytical parameters, and the invention also relates to three such important alternative uses. A first use according to the invention is the use of the composition in connection with detection or quantification of the activity of the enzyme tissue plasminogen activator. A first alternative use means that the composition is usd for the detection of soluble fibrin in bioligical fluids, and a second alternative use means that the composition is used for measuring or studying fibrinolytic activity in vitro or in vivo through the addition of the composition and registration of the degradation of the fibrin. |
